A Big Week for Psychedelic Stocks: 2 CEOs Step Down, MDMA Patents and a Phase 3 Trial
Compass Pathways and Small Pharma announce executive shakeup, Mydecine and Awakn push forward with new research
compass pathways
Compass Pathways Appoints a New CEO
George Goldsmith will be replaced as Compass Pathways CEO. Is this good or bad news?
Compass Pathways Psilocybin Patent Upheld
Compass Pathways scores a major victory in their bid to patent Comp 360, a proprietary formulation of psilocybin.
Comparing MindMed, Atai Life Sciences, Compass Pathways: A Psychedelic Stock Analysis
Our resident psychedelic investor explains a handful of important metrics to study when analyzing and comparing psychedelic stocks.
Psychedelic Business Spotlight – May 6
This week in psychedelic business news: Wesana Health pivots strategy; Compass Pathways makes progress on anorexia; Completion launches psychedelic VR NFTs.
Compass Pathways Shares ‘Promising’ Data That Psilocybin May Treat Anorexia
There is currently no FDA-approved treatment for anorexia. Could psychedelics be the answer?
Kevin O’Leary Predicts These 3 Psychedelic Companies Will Merge, But Should They?
Our resident Psychedelic Investor James Hallifax wonders if the “Shark Tank” star’s prediction makes financial sense.
5 Most Important Psychedelic Clinical Trials in 2022
Here’s why we think MAPS’ second Phase 3 MDMA trial is the most important psychedelic study of 2022, and 4 more that may have huge impacts.
Psychedelic Business Spotlight – March 25
This week in psychedelic business news: Filament Health scores 2nd psilocybin patent; a new psychedelics company emerges as one crumbles.
Top 5 Most Influential Psychedelic Studies
We unpack five of the most important psychedelic studies conducted in recent years as psychedelics become mainstream medicine.
End of content
End of content